SAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that it will host a Key Opinion Leader luncheon for investors focused on the treatment of angiosarcoma and metastatic castration-resistant prostate cancer (mCRPC) at 12:00pm Eastern Time on Thursday, December 1, 2016. This meeting will feature keynote presentations by key opinion leaders Mrinal M. Gounder, M.D., from Memorial Sloan Kettering Cancer Center (MSKCC), who will provide an overview of the unmet need in angiosarcoma and discuss current and novel approaches to therapy, and Scott T. Tagawa, M.D., M.S., from the New York Presbyterian - Weill Cornell Medical Center (WCMC), who will provide an overview of the unmet need in mCRPC and discuss current and novel approaches to therapy. Members of the TRACON executive management team will provide an update on the Company's developmental pipeline, including their lead compound, TRC105 (carotuximab), a novel antibody to endoglin, which is currently being studied in multiple Phase 2 clinical trials sponsored by TRACON and the National Cancer Institute for the treatment of solid tumor types in combination with VEGF inhibitors. Management will also provide an overview of TRC253, a Phase 1/2-ready novel small molecule high affinity antagonist of wild type and mutated androgen receptors, including mutations associated with resistance to Xtandi® (enzalutamide). Dr. Gounder is a practicing medical oncologist at MSKCC, specializing in the care of patients with sarcomas of soft tissue and bone. Dr. Gounder's research interest is to further unravel the complexity of each type of sarcoma and develop new drugs in order to move away from the "one size fits all" paradigm. Currently, he is the lead investigator on several clinical trials for the treatment of sarcomas. He is also an attending physician in the Phase I Clinical Trials program, where he focuses his research on discovering and developing new compounds that are more effective in treating all solid tumors and that are less toxic for the patient. Dr. Gounder is also the Scientific Director of the Desmoid Tumor Research Foundation. Prior to arriving at MSKCC, he completed his internal medicine training at Northwestern University in Chicago, and received his M.D. from SUNY-Syracuse.